Searchable abstracts of presentations at key conferences on calcified tissues

ba0001pp38 | Bone biomechanics and quality | ECTS2013

Bisphosphonate influence on bone quality at molecular level: study of human jaw bone sequesters by Raman microspectroscopy

Olejnik Cecile , Falgayrac Guillaume , During Alexandrine , Vieillard Marie-Helene , Maes Jean Michel , Cortet Bernard , Penel Guillaume

Bisphosphonates (BP) are used as anti-resorptive drugs in benign (osteoporosis) and malignant (myeloma, bone metastasis) bone diseases. Their high affinity for biominerals allows prolonged storage within bone. However information about molecular impact of BP on bone quality are missing. Better understanding of BP properties to optimize their clinical use is needed. The aim of this study was thus to investigate human bone physicochemical changes upon BP uptake.<p class="abs...

ba0001pp270 | Genetics | ECTS2013

SQSTM1/P392L post-zygotic mutations in unrelated patients with Paget's disease of bone

Guay-Belanger Sabrina , Gagnon Edith , Morissette Jean , Brown Jacques P , Michou Laetitia

Introduction: Paget’s disease of bone (PDB) has an autosomal-dominant mode of inheritance in one-third of cases. The germinal SQSTM1/P392L mutation is the most frequent mutation, present in 40% of patients with a familial form of PDB, and 8% of unrelated patients. Fibrous dysplasia (FD) is a rare bone disorder, mono or polyostotic, caused by post-zygotic mutations in GNAS gene, for which a PCR-clamping method was developed to ease their detection and avo...

ba0001pp400 | Osteoporosis: treatment | ECTS2013

Osteonecrosis of the jaw and non-malignant disease

Coudert Amelie , Lescaille Geraldine , Baaroun Vanessa , Azerad Jean , Cohen-Solal Martine , Berdal Ariane , Descroix Vianney

Bisphosphonates (BP) are powerful bone resorption inhibitors. They are used for the symptomatic treatment of malignant osteolytic bone disease (e.g. multiple myeloma and bone metastasis), as well as bone diseases associated with high bone resorption (e.g. postmenopausal osteoporosis, cortisone-induced osteoporosis). However, recent data showed that a rare, but serious, adverse effect of BP therapy is osteonecrosis of the jaw (BRONJ). Given the increasing number of persons rece...

ba0002p31 | (1) | ICCBH2013

Craniofacial consequences of high dose zoledronic acid injections in onco-pediatric patients

Lezot Frederic , Chesneau Julie , Battaglia Severine , Brion Regis , Farges Jean-Christophe , Heymann Dominique , Redini Francoise

Background: High doses of zoledronic acid (ZOL), one of the most potent inhibitors of bone resorption; is currently evaluated in a phase III clinical trial in Europe for the treatment of malignant pediatric primary bone tumors. The impact of such an intensive treatment on the craniofacial skeleton is a critical question in the context of patients with actively growing skeleton; in particular in the light of our previous studies evidencing that endochondral bone formation was t...

ba0002p41 | (1) | ICCBH2013

Management of a new case of neonatal hypocalciuric hypercalcemia related to mutation of the calcium-sensing receptor gene with bone abnormalities

Edouard Thomas , Mouly Celine , Mimoun Emmanuelle , Gennero Isabelle , Magdelaine Corinne , Salles Jean Pierre

Background: A 5-month-old girl was referred to our unit after a systemic screening for hip dislocation by X-rays revealed bilateral femoral bowing. She was the first child of healthy non-consanguineous parents, and her family history was unremarkable. Her parents had a normal physical examination, and normal laboratory findings. At presentation, her height was 64.0 cm (Z-score: 0.0) with a regular height velocity. Weight was 7.4 kg (Z-score: 1.0). On physical...

ba0002p48 | (1) | ICCBH2013

Pubertal induction with testosterone of a boy with bilateral anorchia guided by the development of his monozygotic twin brother

Van Caenegem Eva , Vandewalle Sara , Taes Youri , Kaufman Jean-Marc , Craen Margarita , Guy T'Sjoen

Introduction: We describe a monozygotic twin pair, of which one boy was diagnosed with anorchia. Both were followed-up till age 17.Case report: At birth, in one twin 46 XY boy (A), testes were not palpable while his brother (B) was unaffected. Stimulation with human chorionic gonadotrophin (hCG) and orchidopexia were unsuccessful at age 3. A second hCG-stimulation test was performed at age 8, where serum testosterone response failed to increase. No testi...

ba0002p80 | (1) | ICCBH2013

Osteogenesis imperfecta and short stature: effect of sclerostin antibody treatment in oim/oim mice

Cardinal Mickael , Nyssen-Behets Catherine , Ominsky Mike , Devogelaer Jean-Pierre , Manicourt Daniel H

Introduction: Osteogenesis imperfecta (OI) is characterized by low bone mass, skeletal fragility and, frequently, short stature. We previously showed in oim/oim mice that sclerostin inhibition increased bone mass, mineral content and strength. Here, we compared the body length and the sizes of long bones, head and vertebrae between oim/oim and wildtype mice and analyzed the effect of sclerostin antibody (Scl-Ab) on these parameters.Materials and methods:...

ba0002p125 | (1) | ICCBH2013

Growth plate modifications in lysophosphatidic acid LPA1 receptor-invalidated mice

Gennero Isabelle , Laurencin-Dalicieux Sara , Conte-Auriol Francoise , Briand-Mesange Fabienne , Chun Jerold , Salles Jean-Pierre

Objectives: Lysophosphatidic acid (LPA) is a potent lipid growth factor which possess several G protein-coupled receptors LPA1-6. We have recently demonstrated that LPA1 receptor-invalidated mice display abnormal bone development and osteoporosis, suggesting abnormal endochondral ossification. We have here further studied the growth plates of LPA1 receptor-invalidated mice.Methods: We performed a microscopic and immuno-histochemistry analysis of the femo...

ba0002p131 | (1) | ICCBH2013

Ghrelin differentiates human osteoblasts via GHS-R1a receptor

Gennero Isabelle , Barre Ronan , Conte-Auriol Francoise , Beton Nicolas , Salles Jean Pierre

Objectives: Ghrelin is a peptide hormone secreted in the stomach, which stimulates GH release and food intake. It is also known to have an effect on bone metabolism. The ghrelin specific receptor, GHS-R1a, belongs to the G protein-coupled receptors (GPCRs). Its downstream pathway in osteoblasts remains unclear. We attempted to clarify the way by which ghrelin acts on osteoblast differentiation.Methods: We studied two human osteosarcoma cell lines, MG63 a...